Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis

Background: Disease progression and treatment efficacy vary among individuals with multiple sclerosis. Reliable predictors of individual disease outcomes are lacking. Objective: To examine the accuracy of the early prediction of 12-year disability outcomes using clinical and magnetic resonance imaging (MRI) parameters. Methods: A total of 177 patients from the original Avonex-Steroids-Azathioprine study were included. Participants underwent 3-month clinical follow-ups. Cox models were used to model the associations between clinical and MRI markers at baseline or after 12 months with sustained disability progression (SDP) over the 12-year observation period. Results: At baseline, T2 lesion number, T1 and T2 lesion volumes, corpus callosum (CC), and thalamic fraction were the best predictors of SDP (hazard ratio (HR) = 1.7–4.6; p ⩽ 0.001–0.012). At 12 months, Expanded Disability Status Scale (EDSS) and its change, number of new or enlarging T2 lesions, and CC volume % change were the best predictors of SDP over the follow-up (HR = 1.7–3.5; p ⩽ 0.001–0.017). A composite score was generated from a subset of the best predictors of SDP. Scores of ⩾4 had greater specificity (90%–100%) and were associated with greater cumulative risk of SDP (HR = 3.2–21.6; p < 0.001) compared to the individual predictors. Conclusion: The combination of established MRI and clinical indices with MRI volumetric predictors improves the prediction of SDP over long-term follow-up and may provide valuable information for therapeutic decisions.

[1]  R. Zivadinov,et al.  Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis , 2009, Multiple sclerosis.

[2]  K. Schmierer,et al.  Assessing treatment response to interferon-β , 2014, Neurology.

[3]  M. Calabrese,et al.  The predictive value of gray matter atrophy in clinically isolated syndromes , 2011, Neurology.

[4]  M. Dwyer,et al.  Thalamic atrophy is associated with development of clinically definite multiple sclerosis. , 2013, Radiology.

[5]  R. Rudick,et al.  Significance of T2 lesions in multiple sclerosis: A 13‐year longitudinal study , 2006, Annals of neurology.

[6]  À. Rovira,et al.  Predictive value of early brain atrophy on response in patients treated with interferon β , 2015, Neurology: Neuroimmunology & Neuroinflammation.

[7]  Maria Assunta Rocca,et al.  Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis , 2013, Neurology.

[8]  D. Bourdette,et al.  Inter‐ and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS) , 1992, Neurology.

[9]  R. Rudick,et al.  Predictors of long‐term outcome in multiple sclerosis patients treated with interferon beta , 2013, Annals of neurology.

[10]  L. Kappos,et al.  Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study , 2012, The Lancet Neurology.

[11]  M. Sormani,et al.  Validation of 1‐year predictive score of long‐term response to interferon‐β in everyday clinical practice multiple sclerosis patients , 2015, European journal of neurology.

[12]  R. Rudick,et al.  Defining interferon β response status in multiple sclerosis patients , 2004 .

[13]  Robert Zivadinov,et al.  Gray matter atrophy and disability progression in patients with early relapsing–remitting multiple sclerosis A 5-year longitudinal study , 2009, Journal of the Neurological Sciences.

[14]  Anthony Traboulsee,et al.  Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[15]  F. Barkhof,et al.  Association between MRI parameters and the MS severity scale: a 12 year follow-up study , 2009, Multiple sclerosis.

[16]  A. Janssens,et al.  Callosal lesion predicts future attacks after clinically isolated syndrome , 2009, Neurology.

[17]  J. Lechner-Scott,et al.  Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. , 2015, JAMA neurology.

[18]  R. Rudick,et al.  Defining interferon beta response status in multiple sclerosis patients. , 2004, Annals of neurology.

[19]  M. Horsfield,et al.  Gray matter damage predicts the accumulation of disability 13 years later in MS , 2013, Neurology.

[20]  B Stubinski,et al.  Scoring treatment response in patients with relapsing multiple sclerosis , 2013, Multiple sclerosis.

[21]  E. Havrdová,et al.  Early predictors of non‐response to interferon in multiple sclerosis , 2012, Acta neurologica Scandinavica.

[22]  Dana Horakova,et al.  Volumetric MRI Markers and Predictors of Disease Activity in Early Multiple Sclerosis: A Longitudinal Cohort Study , 2012, PloS one.

[23]  M. Dwyer,et al.  Subcortical and Cortical Gray Matter Atrophy in a Large Sample of Patients with Clinically Isolated Syndrome and Early Relapsing-Remitting Multiple Sclerosis , 2012, American Journal of Neuroradiology.

[24]  J. Lechner-Scott,et al.  Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis , 2015, Annals of neurology.

[25]  C. Pozzilli,et al.  Sustained disability improvement is associated with T1 lesion volume shrinkage in natalizumab-treated patients with multiple sclerosis , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[26]  J H Simon,et al.  Eight-year follow-up study of brain atrophy in patients with MS , 2002, Neurology.

[27]  O. Ciccarelli,et al.  Brain atrophy and lesion load predict long term disability in multiple sclerosis , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[28]  C. Polman,et al.  Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study , 2009, The Lancet Neurology.

[29]  D. Ramasamy,et al.  Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β‐1a , 2015, European journal of neurology.

[30]  R. Rudick,et al.  Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.

[31]  A. Thompson,et al.  The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. , 1998, Brain : a journal of neurology.

[32]  E. Havrdová,et al.  Corpus Callosum Atrophy – A Simple Predictor of Multiple Sclerosis Progression: A Longitudinal 9-Year Study , 2012, European Neurology.

[33]  E. Havrdová,et al.  Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort , 2012, Clinical Neurology and Neurosurgery.

[34]  Maria Assunta Rocca,et al.  Thalamic damage and long-term progression of disability in multiple sclerosis. , 2010, Radiology.

[35]  J Sastre-Garriga,et al.  Measures in the first year of therapy predict the response to interferon β in MS , 2009, Multiple sclerosis.